A Rating Scale for Drug-Induced Akathisia
1989/05/01 by Thomas R. E. Barnes · 2,183 citations
Medicine · Psychology · #Akathisia #Antipsychotic #Clinical psychology #Developmental psychology #Distress #Epilepsy research and treatment #Neurological and metabolic disorders #Psychiatry #Psychology #Rating scale #Schizophrenia (object-oriented programming) #Schizophrenia research and treatment
paper · doi:10.1192/bjp.154.5.672
published in The British Journal of Psychiatry 154(5), 672-676 (Cambridge University Press)
openalex publication_date 1989/05/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Abstract
A rating scale for drug-induced akathisia has been derived that incorporates diagnostic criteria for pseudoakathisia, and mild, moderate, and severe akathisia. It comprises items for rating the observable, restless movements which characterise the condition, the subjective awareness of restlessness, and any distress associated with the akathisia. In addition, there is an item for rating global severity. A standard examination procedure is recommended. The inter-rater reliability for the scale items (Cohen's kappa) ranged from 0.738 to 0.955. Akathisia was found in eight of 42 schizophrenic in-patients, and nine had pseudoakathisia, where the typical sense of inner restlessness was not reported.
Citations
Cited by
- Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review
- Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation
- Association between depressive symptoms, CRP and metabolism-related indicators in Han Chinese patients with chronic schizophrenia
- Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial
- A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
- Schizophrenia Following Early Adolescence Prodrome: A Neurodevelopmental Subtype With Autism-like Sensorimotor and Social Cognition Deficits
- Olanzapine
- The Assessment and Treatment of Antipsychotic-Induced Akathisia
- Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo
- A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder
- Combining actigraphy, ecological momentary assessment and neuroimaging to study apathy in patients with schizophrenia
- Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study
- Mental health nurse prescribing: issues for the UK
- Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
- Maintenance treatment with antipsychotic drugs for schizophrenia
- Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
- A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes
- The Causes of Underdiagnosing Akathisia
- Valproate for acute mood episodes in bipolar disorder
- A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder
- Early intervention for psychosis
- Brexpiprazole: so far so good
- The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing
- Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies
- Comparative Study of Extrapyramidal Side Effects, Sexual Dysfunctions and Hyperprolactinaemia Using Typical and Atypical Antipsychotic Medications Among Patients with Schizophrenia in Maidugri
- A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. [europepmc]
- Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. [europepmc]
- Extrapyramidal side-effects of antipsychotics in a randomised trial. [europepmc]
- Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. [europepmc]
- A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). [europepmc]
- Genomewide association study of movement-related adverse antipsychotic effects. [europepmc]
- 1H-MRS at 4 tesla in minimally treated early schizophrenia. [europepmc]
- Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. [europepmc]
- Olanzapine versus other atypical antipsychotics for schizophrenia. [europepmc]
- High dose D-serine in the treatment of schizophrenia. [europepmc]
- Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. [europepmc]
- A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). [europepmc]
- Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. [europepmc]
- Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. [europepmc]
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. [europepmc]
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. [europepmc]
- The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia. [europepmc]
- What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? [europepmc]
- A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. [europepmc]
- Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. [europepmc]
- Multimodal Neuroimaging in Schizophrenia: Description and Dissemination. [europepmc]
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. [europepmc]
- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. [europepmc]
- Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial. [europepmc]
- Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. [europepmc]
Related